August 17, 2021
Papyrus Therapeutics Inc. is delighted to announce that Marc Beer has been appointed as chairman of the Board of Directors.
Marc brings more then 30 years of therapeutic development and commercialization experience in biotechnology, pharmaceuticals, device and diagnostics. Marc most recently became Executive Chairman of BioTE Medical, a global leader in Precision and Preventive Medicine focused on hormone development and commercialization of optimized hormones for women and men. Additionally, Marc recently became the non-Executive Chairman of Origami Surgical, a patented portfolio of products engineered to enhance robotic assisted surgery and to improve safety, autonomy and surgical efficiency.
Marc founded Renovia Inc., a leading digital therapeutic company focused on women’s healthcare. Marc is the former Chief Executive Officer of Aegerion Pharmaceuticals (NASDAQ:AEGR), which he took public in October, 2010. The company successfully launched two rare disease therapeutics. Previously, Marc founded and took public Viacell Inc. (NASDAQ:VIAC), a leader in cell therapy development and commercialization. Marc sold Viacell to Perkin Elmer (NYSE:PKI) in 2007. Marc was previously the founding Chairman of Erytech Pharma (NASDAQ:ERYP), also founding Chairman of Good Start Genetics (GSG) which was recently acquired by InVitae (NASDAQ:NVTA), and founding Chairman of Minerva (NASDAQ:NERV), which went public in 2013. Prior, Marc held several leadership roles at Genzyme, responsible for the commercial launch of several therapeutic proteins addressing rare disease populations.
Marc is a member of the Miami University Business Advisory Council and previously a member of the Notre Dame Research and Commercialization Advisory Committee and the Notre Dame Graduate Studies Research and Advisory Council. Marc holds a BS from Miami University (Ohio).
Dr. Paul Blake